HK1217334A1 - β-內酰胺酶抑制劑 - Google Patents

β-內酰胺酶抑制劑

Info

Publication number
HK1217334A1
HK1217334A1 HK16104964.6A HK16104964A HK1217334A1 HK 1217334 A1 HK1217334 A1 HK 1217334A1 HK 16104964 A HK16104964 A HK 16104964A HK 1217334 A1 HK1217334 A1 HK 1217334A1
Authority
HK
Hong Kong
Prior art keywords
lactamase inhibitors
beta lactamase
beta
inhibitors
lactamase
Prior art date
Application number
HK16104964.6A
Other languages
English (en)
Inventor
克里斯多佛‧
‧伯恩斯
丹尼斯‧戴格爾
斌‧劉
丹尼爾‧麥加利
丹尼爾‧
‧佩維爾
羅伯特‧
‧李‧特勞特
Original Assignee
Venatorx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venatorx Pharmaceuticals Inc filed Critical Venatorx Pharmaceuticals Inc
Publication of HK1217334A1 publication Critical patent/HK1217334A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK16104964.6A 2012-12-07 2016-04-29 β-內酰胺酶抑制劑 HK1217334A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734900P 2012-12-07 2012-12-07
US201361783238P 2013-03-14 2013-03-14
PCT/US2013/073428 WO2014089365A1 (en) 2012-12-07 2013-12-05 Beta-lactamase inhibitors

Publications (1)

Publication Number Publication Date
HK1217334A1 true HK1217334A1 (zh) 2017-01-06

Family

ID=50884012

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104964.6A HK1217334A1 (zh) 2012-12-07 2016-04-29 β-內酰胺酶抑制劑

Country Status (17)

Country Link
US (5) US9422314B2 (zh)
EP (2) EP3922635A1 (zh)
JP (2) JP6403219B2 (zh)
KR (1) KR102147420B1 (zh)
CN (1) CN105026407B (zh)
AU (1) AU2013355110B2 (zh)
BR (1) BR112015013123B1 (zh)
CA (1) CA2893943C (zh)
ES (1) ES2878118T3 (zh)
HK (1) HK1217334A1 (zh)
HR (1) HRP20210879T1 (zh)
IL (1) IL239212B (zh)
PL (1) PL2928898T3 (zh)
PT (1) PT2928898T (zh)
RU (1) RU2654692C2 (zh)
WO (1) WO2014089365A1 (zh)
ZA (1) ZA201504200B (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE048859T2 (hu) 2010-08-10 2020-08-28 Rempex Pharmaceuticals Inc Gyûrûs bórsavészter származékok, eljárás elõállításukra, és terápiás alkalmazásuk
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
RU2654692C2 (ru) * 2012-12-07 2018-05-22 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамаз
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104981239B (zh) 2013-01-04 2019-01-04 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104994844A (zh) * 2013-01-04 2015-10-21 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
JP6346904B2 (ja) 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
ES2972939T3 (es) 2014-05-05 2024-06-17 Melinta Therapeutics Inc Síntesis de sales de boronato
EP3139930A4 (en) 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
CN106459096B (zh) * 2014-05-19 2019-03-08 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
PT3154989T (pt) 2014-06-11 2021-05-18 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA2952968A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10364257B2 (en) 2014-12-19 2019-07-30 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
US10336702B2 (en) 2014-12-23 2019-07-02 Bergenbio Asa Pharmaceutically active compounds
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
WO2017100537A1 (en) * 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) * 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
BR112018077015B1 (pt) 2016-06-30 2022-05-03 Qpex Biopharma, Inc Derivados de ácido borônico e usos terapêuticos dos mesmos
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
GB201613946D0 (en) * 2016-08-15 2016-09-28 Univ Oslo Compounds
IL301591A (en) * 2017-03-06 2023-05-01 Venatorx Pharmaceuticals Inc Solid forms and combined preparations containing beta-lactamase inhibitor and their uses
TW201841642A (zh) * 2017-04-28 2018-12-01 日商大日本住友製藥股份有限公司 雜環衍生物
GB201708002D0 (en) 2017-05-18 2017-07-05 Univ Oxford Innovation Ltd ß-Lactamase inhibitors
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2019075084A1 (en) 2017-10-11 2019-04-18 Qpex Biopharma, Inc. BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF
CN111556872B (zh) * 2017-11-01 2024-05-10 梅琳塔治疗公司 硼酸酯衍生物的合成及其用途
AU2019256351B2 (en) 2018-04-20 2024-02-29 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CA3098433A1 (en) * 2018-04-27 2019-10-31 Sumitomo Dainippon Pharma Co., Ltd. Oxo-substituted compound
CN112469725A (zh) * 2018-05-25 2021-03-09 维纳拓尔斯制药公司 青霉素结合蛋白抑制剂
EP3849562B1 (en) 2018-09-12 2024-06-26 Venatorx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
KR20210146979A (ko) * 2019-04-02 2021-12-06 베나토알엑스 파마슈티컬스, 인크. 경구 전달 베타-락타마제 억제제의 고체 형태 및 이의 용도
US20230038124A1 (en) 2019-10-25 2023-02-09 Sumitomo Pharma Co., Ltd. Novel substituted condensed ring compound
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
JP2023538645A (ja) * 2020-08-20 2023-09-08 フェーノ・セラピューティクス・カンパニー・リミテッド ボロン酸化合物
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
WO2022187362A1 (en) * 2021-03-02 2022-09-09 Case Western Reserve University Β-lactamase inhibitors and uses thereof
BR112023017203A2 (pt) * 2021-04-13 2023-11-07 Tuojie Biotech Shanghai Co Ltd Derivado de ácido bórico que age como inibidor de beta-lactamase
WO2023155869A1 (zh) * 2022-02-18 2023-08-24 辉诺生物医药科技（杭州）有限公司 新的硼酸类化合物的晶型及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ177159A (en) 1974-04-20 1978-03-06 Beecham Group Ltd Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions
IT1283467B1 (it) * 1996-07-19 1998-04-21 Menarini Farma Ind Derivati di cicloalcani 1,2 sostituiti come inibitori della trombina, procedimento per la loro preparazione e loro impiego in formulazioni
DE60004685T2 (de) 1999-09-17 2004-07-29 Abbott Gmbh & Co. Kg Pyrazolopyrimidine als arzneimittel
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
CA2528587A1 (en) * 2003-06-10 2005-01-20 Fulcrum Pharmaceuticals, Inc. .beta.-lactamase inhibitors and methods of use thereof
PL1756121T3 (pl) 2004-03-30 2012-02-29 Millennium Pharm Inc Synteza związków w postaci estrów i kwasów boronowych
CN1965838A (zh) 2005-11-17 2007-05-23 李海超 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物
ES2428824T3 (es) 2005-12-07 2013-11-11 Basilea Pharmaceutica Ag Combinaciones útiles de antibióticos de monobactama con inhibidores de beta-lactamasa
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
CN101983203A (zh) 2007-11-13 2011-03-02 诺瓦提斯国际药物有限公司 β-内酰胺酶抑制剂
NZ586861A (en) 2008-01-18 2011-12-22 Merck Sharp & Dohme Nitrogen-containing bridged ring compounds as beta-lactamase inhibitors
AR076667A1 (es) 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa
AU2010281439A1 (en) 2009-07-28 2012-03-15 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
HUE048859T2 (hu) * 2010-08-10 2020-08-28 Rempex Pharmaceuticals Inc Gyûrûs bórsavészter származékok, eljárás elõállításukra, és terápiás alkalmazásuk
WO2013014497A1 (en) 2011-07-26 2013-01-31 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
WO2013032012A1 (ja) 2011-09-04 2013-03-07 株式会社糖鎖工学研究所 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
EP2793900B1 (en) 2011-12-22 2018-08-22 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
ES2615744T3 (es) 2012-12-03 2017-06-08 F. Hoffmann-La Roche Ag Compuestos de ácido triazol-borónico sustituidos
RU2654692C2 (ru) 2012-12-07 2018-05-22 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамаз
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104994844A (zh) 2013-01-04 2015-10-21 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
CN104981239B (zh) 2013-01-04 2019-01-04 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
JP6346904B2 (ja) * 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
CN106459096B (zh) 2014-05-19 2019-03-08 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US20150361107A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
PT3154989T (pt) 2014-06-11 2021-05-18 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361108A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US9949982B2 (en) 2014-09-04 2018-04-24 Shionogi & Co., Ltd. Preparation containing cephalosporin having a catechol moiety
US10364257B2 (en) 2014-12-19 2019-07-30 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
IL301591A (en) 2017-03-06 2023-05-01 Venatorx Pharmaceuticals Inc Solid forms and combined preparations containing beta-lactamase inhibitor and their uses
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2019118358A1 (en) 2017-12-11 2019-06-20 VenatoRx Pharmaceuticals, Inc. Hepatitis b capsid assembly modulators
CN112469725A (zh) 2018-05-25 2021-03-09 维纳拓尔斯制药公司 青霉素结合蛋白抑制剂

Also Published As

Publication number Publication date
CA2893943A1 (en) 2014-06-12
BR112015013123B1 (pt) 2021-02-17
US9828391B2 (en) 2017-11-28
US8912169B2 (en) 2014-12-16
RU2654692C2 (ru) 2018-05-22
JP6403219B2 (ja) 2018-10-10
EP2928898B1 (en) 2021-04-14
AU2013355110A1 (en) 2015-07-02
HRP20210879T1 (hr) 2021-08-20
PL2928898T3 (pl) 2021-10-25
US20160326189A1 (en) 2016-11-10
US10669290B2 (en) 2020-06-02
US10214547B2 (en) 2019-02-26
WO2014089365A1 (en) 2014-06-12
US20180194783A1 (en) 2018-07-12
ZA201504200B (en) 2017-09-27
BR112015013123A2 (pt) 2017-07-11
IL239212A0 (en) 2015-07-30
JP2016502973A (ja) 2016-02-01
IL239212B (en) 2019-10-31
KR20150109348A (ko) 2015-10-01
RU2015126912A (ru) 2017-01-12
CN105026407A (zh) 2015-11-04
US9422314B2 (en) 2016-08-23
JP2018184409A (ja) 2018-11-22
US20140171390A1 (en) 2014-06-19
CN105026407B (zh) 2017-09-08
KR102147420B1 (ko) 2020-08-25
US20190225628A1 (en) 2019-07-25
ES2878118T3 (es) 2021-11-18
EP2928898A1 (en) 2015-10-14
EP3922635A1 (en) 2021-12-15
CA2893943C (en) 2021-03-02
PT2928898T (pt) 2021-07-05
AU2013355110B2 (en) 2017-11-09
US20150291630A1 (en) 2015-10-15
EP2928898A4 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
HK1217334A1 (zh) β-內酰胺酶抑制劑
HK1217446A1 (zh) β-內酰胺酶抑制劑
HK1207071A1 (zh) 用作β-內酰胺酶抑制劑的雜二環化合物
HK1212348A1 (zh) 自分泌運動因子抑制劑
HK1212681A1 (zh) 葡糖神經酰胺合酶抑制劑
IL234845A0 (en) Isocazole as a beta-lactamase inhibitor
HK1205739A1 (zh) β-分泌酶抑制劑
IL265496A (en) bace1 inhibitors
HK1216531A1 (zh) 新的抑制劑
HK1209422A1 (zh) 抑制劑
HK1211586A1 (zh) β-分泌酶抑制劑
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
EP2847201A4 (en) 6-oxo-purin-phosphoribosyl INHIBITORS
IL238391A (en) Rock inhibitors
EP2882430A4 (en) ANTIBACTERIAL INHIBITORS
ZA201504305B (en) Autotaxin inhibitors
AP2015008541A0 (en) Autotaxin inhibitors
GB201223308D0 (en) Enzyme inhibitors
GB201210390D0 (en) Antibacterial enzyme inhibitors
GB201200094D0 (en) Antibacterial enzyme inhibitors